Vaxart (VXRT) Projected to Announce Quarterly Earnings on Thursday

Key Points

• Vaxart is expected to report Q3 2026 results after market close on November 5, with analysts forecasting a loss of $0.03 per share and revenue of $27.20 million. The earnings call is scheduled for November 6 at 4:30 p.m. ET.
• In its previous quarter, Vaxart reported a loss of $0.06 per share, beating estimates by $0.06, while revenue of $27.18 million exceeded expectations.
• Shares recently opened at $0.43, near the lower end of their 52-week range, and analysts maintain a consensus “Hold” rating. Vaxart is developing needle-free oral vaccines for coronavirus, norovirus and influenza.

Vaxart (OTCMKTS:VXRT - Get Free Report) will likely be releasing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.03) per share and revenue of $27.20 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:30 PM ET.

Vaxart (OTCMKTS:VXRT - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.06. Vaxart had a return on equity of 53.04% and a net margin of 15.88%. The company had revenue of $27.18 million during the quarter, compared to analyst estimates of $26.21 million. On average, analysts expect Vaxart to post ($0.68) EPS for the current fiscal year and ($1.03) EPS for the next fiscal year.

Vaxart Price Performance

Shares of OTCMKTS VXRT opened at $0.43 on Friday. The business's 50 day moving average is $0.47 and its two-hundred day moving average is $0.58. Vaxart has a 1-year low of $0.30 and a 1-year high of $0.84. The stock has a market capitalization of $104.79 million, a P/E ratio of 2.69 and a beta of 1.05.

Analysts Set New Price Targets

Separately, Zacks Research raised Vaxart to a "hold" rating in a research note on Thursday, July 9th. One investment analyst has rated the stock with a Hold rating. According to MarketBeat.com, the stock presently has a consensus rating of "Hold".

Vaxart Company Profile

Vaxart, Inc is a biotechnology company focused on developing oral recombinant vaccines delivered in tablet form. Its proprietary platform is designed to stimulate immune responses at mucosal surfaces, such as those in the nose and mouth, in addition to generating systemic immunity. The company's approach is intended to offer a needle-free alternative to traditional injectable vaccines.

Vaxart's development programs have included oral vaccine candidates for coronavirus infections, norovirus and influenza.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.